nejm tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants VisualAbstract: Tirzepatide Improved Outcomes in

On September 16, 2025 , the FDA issued warning letters to more than 50 compounding pharmacies and telehealth companies , including Hims & Hers , for selling unapproved GLP-1s and making misleading claims

0.5 mg : After the initial period, you move up to 0.5 mg for another four weeks, at least

*Compounded medications only Medication included Flat monthly cost No dose-based price increases Ongoing provider oversight Delivered to your door Compounded Tirzepatide $375/month Both medications help regulate appetite and blood sugar they work a little differently

This loss accelerates during perimenopause and menopause due to declining estrogen levels